Di Bello M, Lucchini V, Chiari S, Colleoni R, Colombo N, Mantovani A, Allavena P
Laboratory of Human Immunology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Cancer Immunol Immunother. 1988;27(1):63-8. doi: 10.1007/BF00205760.
Expression of HLA-DR antigens by purified preparations of human ovarian carcinoma cells freshly isolated from surgical specimens was examined in parallel with the capacity of tumor cells to elicit a blastogenic response from autologous lymphocytes in mixed lymphocyte-tumor culture (MLTC) assay. Of 21 tumor preparations, 11 (52%) reacted with monoclonal antibodies 279 and/or 949 specific for a monomorphic determinant of HLA-DR antigens, with heterogeneous positivity, ranging between 30% and 95%. In this series of patients positive MLTC occurred in 8/21 individual experiments. The HLA-DR expression was proportionally similar in tumors giving positive MLTC (4/8 = 50%) and negative MLTC (7/13 = 53%). The lack of correlation between DR expression on tumor cells and stimulatory activity in autologous MLTC and the fact that DR-negative tumors could induce lymphocyte stimulation, support the hypothesis that blastogenesis occurs upon recognition of tumor-associated antigens, different from DR molecules, possibly tumor-specific antigens.
从手术标本中新鲜分离的人卵巢癌细胞纯化制剂中HLA - DR抗原的表达,与肿瘤细胞在混合淋巴细胞 - 肿瘤培养(MLTC)试验中引发自体淋巴细胞增殖反应的能力同时进行检测。在21份肿瘤制剂中,11份(52%)与针对HLA - DR抗原单态决定簇的单克隆抗体279和/或949发生反应,呈异质性阳性,范围在30%至95%之间。在这一系列患者中,8/21个单独实验出现了阳性MLTC。在MLTC呈阳性的肿瘤(4/8 = 50%)和MLTC呈阴性的肿瘤(7/13 = 53%)中,HLA - DR表达比例相似。肿瘤细胞上DR表达与自体MLTC中的刺激活性之间缺乏相关性,以及DR阴性肿瘤可诱导淋巴细胞刺激这一事实,支持了这样一种假说,即增殖反应是在识别不同于DR分子的肿瘤相关抗原(可能是肿瘤特异性抗原)时发生的。